This opportunity is now closed.

Funded PhD Opportunity

Nutrition intervention for healthy blood pressure in pregnancy: impact on placenta development and neonatal wellbeing.

Subject: Biomedical Sciences


Summary

Pregnancy induced hypertension (PIH) affects an estimated 10-15% of all pregnancies and is considered one of the major causes of maternal and prenatal morbidity and mortality (1). Along with established nutrition and lifestyle determinants, genetic factors also contribute to development of high blood pressure (BP), with evidence from Genome-Wide Association Studies implicating the MTHFR gene (encoding the folate-metabolising enzyme methylenetetrahydrofolate reductase). Meta-analyses of prospective observational studies have confirmed the link of MTHFR 677C→T polymorphism with PIH (2) and preeclampsia (3).

In recent years, researchers at Ulster made the novel discovery that riboflavin, the MTHFR co-factor, plays a key role in driving the BP phenotype and risk of hypertension associated with this folate polymorphism. In three randomised controlled trials (RCTs) published to date, we showed that riboflavin supplementation targeted at homozygous individuals (MTHFR 677TT genotype) lowers systolic blood pressure by 6-13 mmHg, independently of the effect of antihypertensive drugs (4-6). The TT genotype affects an estimated 10% of populations worldwide, and 12% of Irish adults.

For people with this genotype riboflavin may offer an effective treatment or preventative strategy for hypertension, but to date this has not been investigated in the context of pregnancy. The placenta is a transient structure where the maternal and fetal vasculatures intersect in order to allow transfer of nutrients and other substances. It is a highly specialised and tightly regulated organ whose functioning has an impact on health and wellbeing of the fetus and neonate, as well as influencing the risk of high BP in childhood and in later life (7, 8). Perturbed growth and development of placental villi occurs in pregnancies complicated by fetal growth restriction (9), PIH and/or preeclampsia (10); however, it is unknown if the MTHFR 677TT genotype can independently affect the development and function of placenta.

The overall aim of this PhD project is to test the use of riboflavin as a non-drug, personalised approach for managing BP in pregnancy in women who are genetically at-risk of higher BP. In addition, the project will investigate the role of MTHFR 677TT genotype on placental development at term, by quantifying morphological, cellular and molecular markers and particularly whether the treatment with riboflavin has a modifying impact on these measures. .

A double-blinded RCT will be conducted on pregnant women recruited in the first trimester of pregnancy. Women will be genotyped for MTHFR 677C→T polymorphism and will be randomised to receive either 5 mg/day riboflavin or placebo from 16 GW until the end of pregnancy. Blood samples and BP measurements will be taken before and at the end of the intervention. Placenta and cord blood samples will be collected at delivery. Blood samples will be analysed for riboflavin and B-vitamin biomarkers whereas placenta samples will be subjected to histological, stereological, immunohistochemical and ultrastructural assessment.

The student will receive full training (human studies and laboratory methods), but previous experience in subject recruitment and/or relevant laboratory techniques would be an advantage.

References:

  1. Macdonald-Wallis C, Silverwood RJ, de Stavola BL, Inskip H, Cooper C, Godfrey KM, Crozier S, Fraser A, Nelson SM, Lawlor DA & Tilling K. Antenatal blood pressure for prediction of pre-eclampsia, preterm birth, and small for gestational age babies: development and validation in two general population cohorts. BMJ 2015;351:h5948.
  2. Yang B, Fan S, Zhi x, Li Y, Liu Y, Wang D, He M, Hou Y, Zheng Q & Sun G. Associations of MTHFR gene polymorphism and hypertension and hypertension in pregnancy: a meta-analysis from 114 studies. PLoS ONE. 2014.9, e87497.
  3. Xia X., Chang W, Cao Y, 2012. Meta-analysis of the methylenetetrahydrofolate reductase C677T polymorphism and susceptibility to pre-eclampsia. Hypertens Res 2012;35(12):1129-34.
  4. Horigan G, McNulty H, Ward M, Strain J, Purvis J & Scott JM. Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the 677C-->T polymorphism in MTHFR. J Hypertens 2010.28:478-86
  5. Wilson CP, McNulty H Ward M et al. (2012). Riboflavin offers a targeted strategy for managing hypertension in patients with the MTHFR C77TT genotype: a 4y follow up. Am J Clin Nutr 95,766-772.
  6. Wilson CP, McNulty H, Scott JM, Strain JJ, Ward M. The MTHFR C677T polymorphism, B-vitamins and blood pressure. Proc Nutr Soc, 2010. 69 156-165.
  7. Barker DJ, Thornburg KL, Osmond C, Kajantie E, Eriksson JG.The surface area of the placenta and hypertension in the offspring in later life. Int J Dev Biol2010;54(2-3):525-30.
  8. Barker D, Osmond C, Grant S, Thornburg KL, Cooper C, Ring S, Davey-Smith G. Maternal cotyledons at birth predict blood pressure in childhood. Placenta 2013 Aug;34(8):672-5.
  9. T.M. Mayhew, C. Ohadike, P.N. Baker, I.P. Crocker, C. Mitchell and S.S. Ong (2003) Stereological investigation of placental morphology in pregnancies complicated by pre-eclampsia with and without intrauterine growth restriction. Placenta 24: 219 – 226.
  10. Jones CP & Fox H. An ultrastructural and ultrahistochemical study of the human placenta in maternal pre-eclampsia. Placenta 1980; 1: 61-76.

Essential criteria

  • To hold, or expect to achieve by 15 August, an Upper Second Class Honours (2:1) Degree or equivalent from a UK institution (or overseas award deemed to be equivalent via UK NARIC) in a related or cognate field.
  • Sound understanding of subject area as evidenced by a comprehensive research proposal

Desirable Criteria

If the University receives a large number of applicants for the project, the following desirable criteria may be applied to shortlist applicants for interview.

  • First Class Honours (1st) Degree
  • Masters at 65%
  • Research project completion within taught Masters degree or MRES
  • Practice-based research experience and/or dissemination
  • Experience using research methods or other approaches relevant to the subject domain
  • Work experience relevant to the proposed project
  • Publications - peer-reviewed
  • Experience of presentation of research findings
  • A comprehensive and articulate personal statement
  • Relevant professional qualification and/or a Degree in a Health or Health related area

Funding

    The University offers the following awards to support PhD study and applications are invited from UK, EU and overseas for the following levels of support:

    Vice Chancellors Research Studentship (VCRS)

    Full award (full-time PhD fees + DfE level of maintenance grant + RTSG for 3 years).

    This scholarship will cover full-time PhD tuition fees and provide the recipient with £15,000 maintenance grant per annum for three years (subject to satisfactory academic performance). This scholarship also comes with £900 per annum for three years as a research training support grant (RTSG) allocation to help support the PhD researcher.

    Vice-Chancellor’s Research Bursary (VCRB)

    Part award (full-time PhD fees + 50% DfE level of maintenance grant + RTSG for 3 years).

    This scholarship will cover full-time PhD tuition fees and provide the recipient with £7,500 maintenance grant per annum for three years (subject to satisfactory academic performance). This scholarship also comes with £900 per annum for three years as a research training support grant (RTSG) allocation to help support the PhD researcher.

    Vice-Chancellor’s Research Fees Bursary (VCRFB)

    Fees only award (PhD fees + RTSG for 3 years).

    This scholarship will cover full-time PhD tuition fees for three years (subject to satisfactory academic performance). This scholarship also comes with £900 per annum for three years as a research training support grant (RTSG) allocation to help support the PhD researcher.

    Department for the Economy (DFE)

    The scholarship will cover tuition fees at the Home rate and a maintenance allowance of £ 15,009 per annum for three years. EU applicants will only be eligible for the fee’s component of the studentship (no maintenance award is provided). For Non-EU nationals the candidate must be "settled" in the UK. This scholarship also comes with £900 per annum for three years as a research training support grant (RTSG) allocation to help support the PhD researcher.

    Due consideration should be given to financing your studies; for further information on cost of living etc. please refer to: www.ulster.ac.uk/doctoralcollege/postgraduate-research/fees-and-funding/financing-your-studies


Other information


The Doctoral College at Ulster University


Reviews

My experience has been great and the people that I have worked with have been amazing

Kieran O'Donnell - 3D printing of biological cells for tissue engineering applications

Watch Video  

Completing the MRes provided me with a lot of different skills, particularly in research methods and lab skills.

Michelle Clements Clements - MRes - Life and Health Sciences

Watch Video  

Throughout my PhD I’ve been provided with continuous support and guidance by my supervisors and the staff at the University.I’ve also received many opportunities to further enhance my professional development in the form of teaching experience and presenting my work at conferences which will aid in my pursuit of a career in academia or industry.

William Crowe


Key dates

Submission deadline
Monday 18 February 2019

Interview Date
Weeks commencing 11, 18, 25 March 2019


Applying

Apply Online  


Campus

Coleraine campus

Coleraine campus
The feeling of community at our Coleraine campus makes for a warm and welcoming student experience.


Contact supervisor

Professor Kristina Pentieva


Other supervisors

Related Funded Opportunities

Role of B-vitamins in Epigenetic Modulation of Hypertension

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences

 View details

Diabetes

Subject: Biomedical Sciences

 View details

Engineering plasmid nanoparticles as a platform for delivery of therapeutics

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences

 View details

Graphene family materials as novel chronic wound therapeutics

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences|Computer Science and Informatics

 View details

Investigation of microRNA regulation and function in prostate cancer

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences

 View details

Role of novel cardiac biomarkers in cellular senescence

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences

 View details

Oxygen-generating biomaterials for use in wound dressing strategies

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences|Computer Science and Informatics

 View details

The regulation of rhamnolipid biosynthesis in Burkholderia thailandensis.

Closing date:
Tuesday 1 September 2020
Subject: Biomedical Sciences

 View details

The production of rhamnolipid biosurfactant by Pseudomonas aeruginosa growing in biofilms.

Closing date:
Tuesday 1 September 2020
Subject: Biomedical Sciences

 View details

Naturally-occurring microbial biosynthetic pathways for propane

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences

 View details

Genomic Medicine

Subject: Biomedical Sciences

 View details

Development and evaluation of a web-based interactive teaching tool for Optometrists

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences|Computer Science and Informatics

 View details

Novel fatty acid receptors in islet cells as therapeutic targets for diabetes

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences

 View details

Interactome visualisation of ALS using virtual reality

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences

 View details

Stratified Medicine

Subject: Biomedical Sciences

 View details

Novel amphibian skin peptide-analogues for the treatment of type-2 diabetes

Closing date:
Friday 18 September 2020
Subject: Biomedical Sciences

 View details

Blue whiting protein hydrolysates for management of sarcopenia

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences

 View details

Targeted exendin/apelin hybrid peptides for diabetes and obesity therapy.

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences

 View details

Optometry and Vision Science

Subject: Biomedical Sciences

 View details

MRes in Biomedical Sciences

Subject: Biomedical Sciences

 View details

Regulation of glucose metabolism by incretin signalling

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences

 View details

Mental Health Diagnosis using Cognitive Analytics

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences|Psychology, Psychiatry and Neuroscience

 View details

Identifying biomarkers that may affect diabetes comorbidity

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences

 View details

The Growing Problem of Myopia: are spectacles part of the problem?

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences

 View details

Improving the screening and diagnosis of familial hypercholesterolemia

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences|Computer Science and Informatics

 View details

Computational approaches to investigate multimorbidity in depression

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences

 View details

The role of dietary fatty acids and the gut microbiota on autoimmunity

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences

 View details

A novel therapeutic targeting the inflammasome as a treatment for glaucoma.

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences

 View details

Nutrition and the gut microbiome: impact on brain health in older adults

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences

 View details

Investigation of oral and blood microbiome shifts in patients with depression.

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences

 View details

Vitamin D across the lifecycle to inform nutritional policies

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences

 View details

Epigenomic Profiling of Young Adults with Mental Health Disorders in Northern Ireland

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences

 View details

Investigation of the modifying effects of selenium in the relationship between methylmercury and child development

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences|Biomedical Sciences

 View details

Towards seeing clearly: does the shape of the eye’s optics affect our focus?

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences

 View details

Changing dietary patterns in the Seychelles and implications for public health

Closing date:
Friday 7 February 2020
Subject: Biomedical Sciences

 View details